BioPharma Resources

Drug Trial Radar · NCT02729571

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

A Randomized, Double-blind, Dose-escalation Clinical Trial of the Safety, Reactogenicity and Immunogenicity of MTBVAC Compared to BCG Vaccine SSI, in Newborns Living in a Tuberculosis Endemic Region With a Safety Arm in Adults

Last checked: Nov 19, 2026Latest source record: May 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Sep 2015

Primary completion

Sep 2016

Study completion Mar 2018

Sponsor

Lead sponsor
Biofabri, S.LIndustry
Sponsor type
Industry
Collaborators
South African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative; Triclinium Clinical Trial Project Management (Pty) Ltd.; Universidad de Zaragoza
First posted
Apr 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 1 day, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, controlled, double blind clinical trial in 2 stages (adult stage, infant stage). The first stage includes 18 HIV uninfected, QFT negative, BCG vaccinated, adult participants, randomized 1:1 to receive BCG Vaccine SSI or MTBVAC at equivalent dose (5x10E05 CFU/0.1mL) (n=9 in each group). Upon favourable safety review by the DSMB for all 18 adults up to day 28 after study vaccination, the second stage will commence in thirty-six (36) HIV unexposed, BCG naïve, newborn infants, randomized 1:3 to receive BCG Vaccine SSI or MTBVAC at one of three different dose levels ( (n=9 in each group).

Conditions

  • Tuberculosis

Interventions

  • MTBVACBiological

    Live-attenuated tuberculosis vaccine

  • BCGBiological

    Commercially available live-attenuated tuberculosis vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and reactogenicity in infants and adults: includes injection site and systemic and regional adverse events, solicited and unsolicited. A diary card will be for solicited local, regional, and systemic adverse event data.Time frame: Six (6) months post-study vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • South African Tuberculosis Vaccine Initiative, Brewelskloof Hospital

    Worcester, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.